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S U M M A R Y
Hepatitis E infection, caused by the hepatitis E virus (HEV), is a common cause of acute hepatitis in
developing countries with poor sanitation and hygiene. The virus is classiﬁed into four genotypes (1–4)
with one serotype. Genotypes 1 and 2 exclusively infect humans, whereas genotypes 3 and 4 also infect
other animals, particularly pigs. In endemic areas, large outbreaks of acute hepatitis caused by viruses of
genotype 1 or 2 frequently occur due to fecal–oral transmission, usually through contamination of
drinking water. With a high attack rate in young adults (aged 15–45 years), the disease is particularly
severe among pregnant women (20–30% mortality). HEV appears to be a zoonotic disease, with
transmission from pigs, wild boars, and deer, or foodborne. Chronic infections are rare, except in
immunosuppressed persons, such as organ transplant recipients. A subunit vaccine has been shown to be
effective in preventing the clinical disease, but is not yet commercially available. Our understanding of
HEV has undergone major changes in recent years and in this article we review the currently available
information with regard to the molecular biology, pathobiology, and epidemiology of HEV infection. We
also review the current therapeutic interventions and strategies being used to control HEV infection,
with emphasis on possible approaches that could be used to develop an effective vaccine against HEV.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Viral hepatitis, caused by any of the ﬁve hepatotropic viruses,
i.e., hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C
virus (HCV), hepatitis D virus (HDV), and hepatitis E virus (HEV),
represents a major health problem worldwide. Among the viruses,
HEV is now established as the major etiological agent of enterically
transmitted non-A, non-B hepatitis. The ﬁrst well-documented
epidemic of hepatitis E infection in India was the epidemic of
1955–56 in New Delhi, affecting a total of 29 000 people; this
occurred due to fecal contamination of drinking water. Although
originally considered to be an epidemic of hepatitis A, retrospec-
tive testing of the stored sera from the affected patients suggested
that a novel infectious agent was responsible.1 Since the early
1990s, following the identiﬁcation and sequencing of its etiological
agent, the disease became known as hepatitis E and its agent as
hepatitis E virus.2 The letter ‘E’ stands for ‘enteric’, ‘epidemic’, or
‘endemic’, all of which are features that adequately describe the
epidemiology of HEV. A high case fatality rate averaging around
20% in pregnant women, particularly in the third trimester, is a
characteristic feature of HEV infection.3,4 HEV is regarded as the* Corresponding author.
E-mail address: subrat_kumar@yahoo.com (S. Kumar).
1201-9712/$36.00 – see front matter  2012 International Society for Infectious Disea
http://dx.doi.org/10.1016/j.ijid.2012.11.026major etiological agent of enterically transmitted non-A hepatitis
in India.5 HEV is responsible for both sporadic and epidemic
outbreaks of acute hepatitis in developing countries, leading to a
self-limiting disease. The global burden of HEV infection is more
due to sporadically transmitted hepatitis E cases than to cases due
to epidemic hepatitis E. Based on the 2010 global burden of
diseases study, it has been estimated that as many as 20.1 million
people were infected with HEV genotypes 1 and 2 in 2005, in nine
regions. This represents 71% of the world’s population, with 3.4
million symptomatic cases, 70 000 deaths, and 3000 stillbirths.6
The death rate was higher among symptomatic pregnant women
that among symptomatic non-pregnant women.6
HEV has been classiﬁed as the type species of the new genus
Hepevirus in the family Hepeviridae.7 Study of the molecular
biology of HEV was signiﬁcantly advanced with the establishment
of an efﬁcient cell culture system8 and an effective vaccine,9 but we
still lack a reliable diagnostic procedure. However, anti-HEV
antibody assays are widely available in European and Asian
countries. Recent ﬁndings in HEV molecular biology, diagnosis, and
pathogenesis are reviewed here.
2. Molecular biology
The genome of HEV is comprised of a single-stranded positive-
sense RNA strand of approximately 7.2 kb and contains three openses. Published by Elsevier Ltd. All rights reserved.
Figure 1. Genomic organization of the hepatitis E virus. The diagram depicts the organization of the genome (7.5 kb). HEV is an RNA virus with three open reading frames
(ORF 1–3) encoding nonstructural and structural proteins (NTR, non-translatable region).
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proteins (Figure 1). ORF 1, present at the 50 end, encodes a 1693
amino acid non-structural polyprotein. This polyprotein undergoes
post-translational modiﬁcations to yield ﬁve different functional
protein products, including a methyltransferase, a y-domain, a
papain like cysteine protease, a helicase, and the RNA-dependent
RNA polymerase. ORF 2, present at the 30 end, encodes the 660–599
amino acid major capsid. ORF3 overlaps the other two ORFs and
encodes a phosphoprotein that may help in replication and
cytoskeleton synthesis. ORF1 contains a hypervariable region
(HVR) that ranges from 557 to 641 amino acids. The HVR overlaps
with the proline-rich sequence that is located between the N-
terminus of the X domain and the C-terminal portion of putative
papain-like protease domain. The HVR varies both in length and in
sequence among different HEV strains.
Research at the Meng Laboratory has recently demonstrated
that HEV can tolerate small deletions in the HVR and maintain its
infectivity, suggesting that the amino acid residues in this region
are dispensable for virus infectivity.10,11 The genome sequence of
HEV is relatively stable, although the genome of strains isolated
from geographically distinct locations are generally more diverse.
Based on whole genome sequencing, HEV has been characterized
into four major genotypes: genotype 1 (Burmese-like Asian
strains12,13), genotype 2 (a single Mexican strain14), genotype 3Figure 2. Geographical distribution of human hepatitis E virus genotypes. Map showing t
are divided into four major genotypes (1–4), and each has its own geographical localiz(strains from rare endemic cases in industrialized countries and
swine HEV strains worldwide15,16), and genotype 4 (variant strains
from endemic cases in Asia and swine HEV strains in Asia17,18). All
swine HEV strains identiﬁed thus far belong to genotype 1, 3, or
4.19–21 The geographic distributions of the various genotypes is
given in Figure 2. The recent discovery of novel lineages of HEV in
rabbits,22,23 rats,24 and a wild boar25 has further expanded the
mammalian host diversity of HEV. These ﬁndings suggest that HEV
has the capacity to be a zoonotic agent.
3. Pathobiology of the virus
Hepatitis E virus infection manifests both as epidemic and
sporadic hepatitis in endemic disease areas. Since the ﬁrst
outbreak of HEV in 1955–56 in Delhi, many more outbreaks have
been reported. During these outbreaks, attack rates of 1–15% (with
a disproportionate number of cases seen in 15- to 40-year-olds)
have been seen. The case fatality rate during epidemics was found
to be between 0.2% and 4%, but an unexplainably high rate of
fulminant liver failure was seen in pregnant women (mortality rate
of around 10–20%). In India, 30–60% of all the sporadic cases of
hepatitis are due to HEV infection.
The primary mode of transmission of HEV is fecal–oral.
Evidence of fecal contamination of drinking water supplies hashe geographical distribution of HEV genotypes among humans. Human HEV isolates
ation.
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most frequently during the rainy season, due to overﬂowing drains
and the use of contaminated water for drinking.26 Outbreaks have
most often been associated with poor personnel hygiene,
inadequate sanitation,27 and an unsafe drinking water supply.28
Overcrowding and refugee camps also exacerbate the problems.29
The clinical outcomes associated with HEV infection are quite
diverse. HEV infection most commonly manifests as self-limiting,
acute icteric hepatitis, which is indistinguishable from acute
hepatitis caused by other hepatotropic viruses. In most cases,
contact with HEV leads to an asymptomatic infection followed by
spontaneous clearance of the virus, and only a minority of patients
develop the symptomatic, icteric course of the disease.6,9 In a
proportion of patients, the illness is particularly severe and
presents as fulminant hepatitis (acute liver failure). In animal
studies, the viral inoculum dose determines the severity of the liver
injury, and lower doses are associated with subclinical infection;
whether this holds true for humans has not yet been studied.30
Kumar et al. carried out a study aimed at characterizing the HEV
isolates from acute viral hepatitis (AVH) and fulminant hepatic
failure (FHF) patients based on the RNA-dependent RNA polymer-
ase (RdRp) region.31 They reported that all the isolates from acute
cases belonged to subtype Ia and that the isolates from fulminant
cases belonged to subtype Ic under genotype 1. This ﬁnding has
raised the possibility of a correlation between disease severity and
HEV isolate subtype. Liver abnormalities and coagulopathy rates
that correlate with the damage to hepatocytes are seen in HEV-
infected individuals. Resolution of biochemical abnormalities
generally occurs within 1 to 6 weeks after the onset of illness,
although some patients have a prolonged illness with prominent
cholestatic manifestations. Chronic infection with HEV is virtually
absent among healthy individuals, and has never been reported
from HEV genotype 1 endemic countries. However, chronic
hepatitis E after infection with HEV genotype 3 has been reported
among persons receiving immunosuppressive treatments follow-
ing organ transplantation.32
Research on neurological sequelae due to HEV infection is
scarce, and reports come mainly from the Indian subcontinent,
where genotype 1 infection is predominant. The role played by
other genotypes in industrialized countries is unknown. Recently,
Kamar et al. detected HEV RNA in the cerebrospinal ﬂuid (CSF) of
four patients out of seven studied for neurological complications
due to HEV infection.33 Although we need more such studies to
conﬁrm these ﬁndings, clinicians should strongly consider the
possibility of HEV infection in patients with neurological disorders
and especially in those patients who also have liver abnormalities
as indicated by blood tests. In a separate study, the same group
highlighted a possible relationship between neurological symp-
toms and HEV infection in a kidney transplant patient.34 They were
also able to show the existence of HEV quasispecies in the serum
and CSF isolated from the patient.34
HEV infection can become chronic hepatitis in immunocom-
promised patients. Several reports have recently been published
on the involvement of HEV in chronic infection, especially in solid
organ transplant cases.35 In endemic areas, HEV infection
occurring in patients with pre-existing chronic liver disease of
any etiology may lead to superimposed acute liver injury and
clinical presentation of acute chronic liver disease. Such patients
may be at higher risk of a poor prognosis. Kamar et al. evaluated
the use of pegylated interferon alpha-2a (peg-IFN-a2a) in the
treatment of chronic HEV in solid organ transplant (liver and
kidney) cases and observed a sustained virological response after
3 months of treatment.36,37 Although peg-IFN-a2a can be used to
effectively treat chronic HEV infection after liver transplantation,
peg-IFN-a2a use for kidney transplant patients is contraindi-
cated. For this reason, Kamar et al. assessed the antiviral effect ofribavirin monotherapy in patients with chronic HEV infection
following a kidney transplant. They observed that ribavirin
monotherapy inhibited the replication of HEV in vivo and led to
normalization of the levels of alanine and aspartate aminotrans-
ferase; however further studies are required to determine the
optimal duration of ribavirin therapy.38 A combination therapy of
peg-IFN-a2a and ribavirin has been reported to be helpful in the
clearance of HEV. Clearance was associated with an improvement
in patient symptoms, a normalization of liver function tests, and a
reduction in inﬂammation and ﬁbrosis of the liver in a patient
with chronic HEV/HIV-1 co-infection.39 Gerolami et al. evaluated
the use of ribavirin to treat severe acute HEV infection in non-
immunocompromised patients and observed a rapid improve-
ment in liver function tests concurrently with a decrease in HEV
RNA levels in serum.40
4. Epidemiological patterns, prevalence, and mode of
transmission
The incubation period of HEV in human volunteers after oral
exposure is normally 4–5 weeks. A more variable incubation
period of 2–10 weeks has been reported during hepatitis E
outbreaks in which the time of water contamination was known.
Research among non-human primates has shown a direct
association between infective dose and disease severity, but an
inverse relationship to the incubation period.41 Four major routes
of transmission of HEV infection have been reported. These are:
(1) fecal–oral transmission due to contamination of drinking
water supplies; (2) foodborne transmission; (3) transfusion of
infected blood products; and (4) vertical transmission. Of these,
transmission through contaminated drinking water seems to be
the most common route. However, in cases in non-endemic
regions and sporadic cases in disease-endemic regions, it is often
not possible to establish the route of acquisition of infection.
Distinct patterns of epidemiology have been seen in the
geographical regions where hepatitis E is endemic compared to
where it is non-endemic. In areas of endemic disease, epidemics of
hepatitis E are more frequent and are usually separated by a few
years. Such outbreaks have been observed in China, the Indian
subcontinent, southeast and central Asia, the Middle East, and the
northern and western parts of Africa. These outbreaks are usually
large, and several hundred to several thousand persons are
affected. Overall attack rates during hepatitis E outbreaks range
from 1% to 15%, with males outnumbering females in most of
them. Unlike several other enterically transmitted infections,
person-to-person transmission of HEV is uncommon.42 In
hepatitis E endemic regions, the presence of HEV viremia among
healthy blood donors and subsequent transmission of this
infection to transfusion recipients has been documented. An
anti-HEV IgG prevalence rate of 7.8% to 45% has been reported in
volunteer blood donors in endemic countries, in contrast to 1–4%
in industrialized countries.43 Baylis et al. reported the presence of
HEV in plasma fractionation pools in Sweden, Germany, and the
USA.44 All these ﬁndings raise the possibility of HEV transmission
via the transfusion of contaminated blood products. Although the
spread of HEV infection through contaminated food is possible,
few outbreaks related to foodborne transmission have been
reported from disease-endemic areas. This may be due to a
relatively long incubation period, which makes it difﬁcult to
establish a relationship between consumption of a particular food
and the occurrence of disease. The role of zoonotic transmission of
HEV in endemic regions remains unclear. Hepatitis E has been
reported in homosexual men,45,46 which suggests a sexual mode
of transmission. Data from endemic areas are scarce, however Bali
et al. reported the spread of hepatitis E in an active group of male
homosexuals in a village in north India.47
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While humans are generally considered to be the natural host
for HEV, there is evidence to suggest that HEV also acts as a
zoonotic virus. In a study carried out in China, the overall
prevalence of anti-HEV IgG in the general human population was
found to range from 32% among individuals who had frequent
contact with swine to 21% among individuals whose contact was
rare. The overall prevalence of anti-HEV in swine older than 3
months is 82%.48 These data suggest that swine infections
contribute to the high prevalence among people who have
frequent direct exposure to animals. In the USA, a signiﬁcant
association of HEV seropositivity and animal contact has been
found in humans who have pets in the home.49 These data do not
necessarily indicate that HEV infections in these people are
exclusively zoonotic and may rather reﬂect a greater exposure of
pet owners to environmental contamination from different
sources, including human waste.
Recent research by different groups also suggests that
foodborne HEV transmission is possible in relation to the ingestion
of raw or undercooked meat and offal from swine.50,51 If so, it
would be expected that a source is infected with a single strain of
virus and that this strain is transmitted to a recipient—therefore,
viral genomic sequences identiﬁed in the two hosts should be
identical or nearly identical. Although few foodborne transmis-
sions have been documented, they provide genetic proof of HEV
strains shared between an animal source and a human host. For
example, the genetic analysis of the HEV strains in the livers of
infected pigs sold at one local grocery store in Hokkaido, Japan,
showed that some HEV variants found in porcine organs were
identical to the HEV genotype 3 and 4 strains recovered from the
local human cases.52 More direct evidence for foodborne
transmission was obtained by Tai et al., who reported a hepatitis
outbreak among family members and some of their friends after
they had eaten uncooked deer meat. Epidemiological studies and
comparison of the RNA sequences of the HEV samples obtained
from these patients and from a frozen portion of the suspect deer
meat showed that they were all infected with HEV genotype 3.53
Another study examined the HEV RNA sequences from wild boars,
a deer, and four patients who had contracted hepatitis E after
eating raw deer meat. The sequences displayed a sequence
similarity of 99.7%. Although direct transmission from deer to
humans could not be established, the sequence similarity
suggested interspecies HEV transmission between boar and deer,
as well as possible foodborne transmission to humans.54 In another
report, a woman whose husband was a boar hunter had eaten boar
meat from one of his kills and became ill with hepatitis E. HEV RNA
sequences from her serum and the consumed boar meat displayed
a sequence similarity of 99.95%, conﬁrming transmission of HEV
from the boar to the woman.55 Additional evidence of foodborne
transmission was obtained from Hokkaido, Japan, where HEV
genotype 4 strains were recovered from a series of sporadic
hepatitis E cases from 2004 to 2009 where the isolates exhibited a
high degree of sequence similarity.56,57With all these ﬁndings, it is
now possible to say that HEV (especially genotypes 3 and 4) can
and often does act as a zoonotic virus infection.
6. Diagnosis
Diagnosis of hepatitis E infection relies on laboratory abnor-
malities in liver enzyme and liver function tests, such as elevated
serum levels of alanine aminotransferase, aspartate aminotrans-
ferase, alkaline phosphatase, bilirubin, and gamma-glutamyltrans-
ferase. Abnormalities in liver function typically coincide with the
onset of clinical symptoms. All these factors indicate a severe
hepatic synthetic defect and extensive hepatocellular necrosis.Histopathological changes in the liver during acute infection
include focal necrosis and modest inﬂammation. Cholestatic
hepatitis is common and a ‘pseudoglandular’ alteration of
hepatocyte plates has been noted. Since cases of hepatitis E are
difﬁcult to distinguish clinically from other types of acute viral
hepatitis, the diagnosis is made by blood tests that detect elevated
HEV antibody levels. HEV infection elicits both IgM and IgG. The
IgM anti-HEV response is rapid, occurring about a month after
infection and peaking at the onset of biochemical abnormalities
and/or symptoms. There are a number of commercial enzyme
immunoassays available for the detection of IgM and IgG anti-HEV
in serum, although there is considerable variability in their
sensitivities and speciﬁcities. This lack of consistency makes
comparison of the diagnosis of HEV infection using different tests
difﬁcult. Drobeniuc et al. conducted a pan-genotypic validation of
six commonly available IgM assays and found that only two of
these assays had sensitivity and speciﬁcity above 95%.58 HEV RNA
can be detected in both blood and stool at the peak of the acute
serological response. Reverse transcriptase polymerase chain
reaction (RT-PCR) can be used to detect HEV RNA in serum and
stool, but unfortunately such tests are not widely available in
commercial laboratories. If laboratory tests are not available, then
epidemiological evidence may help in establishing a diagnosis. The
World Health Organization has established a number of interna-
tional standards (ISs) for nucleic acid ampliﬁcation (NAT)-based
assays for several bloodborne viruses for use in blood and plasma
safety checks.59 Baylis et al. carried out the ﬁrst study comparing
the performances of these assays for the detection of HEV RNA and
investigated the suitability of different HEV strains for the
development of a candidate WHO IS.60 Four virus strains –
genotypes 3a, 3b, 3f, and 4c – were used for this study, and it was
determined that any of these could be used as a potential strain to
develop into an IS. As genotype 3 viruses have the widest
distribution worldwide, they are a good candidate for WHO IS.
More such studies involving other HEV strains are needed to
establish a WHO IS for NAT-based assays for all HEV genotypes.
7. Treatment and control strategy
As fecal–oral transmission is the predominant mode of
transmission of HEV infection, measures aimed at proper
treatment and safe disposal of human excreta, the provision of a
safe drinking water supply, and improvements in personal hygiene
form the keystones of its prevention. Previous attempts at
preventing hepatitis E by administering normal immune globulin
manufactured from plasma obtained in the areas where HEV is
endemic were unsuccessful,61 or results were uncertain.62 As the
populations in regions where HEV is endemic have a relatively low
prevalence and titer of anti-HEV, it is perhaps not surprising that
unscreened batches of normal immune globulin may not contain
protective quantities of anti-HEV antibodies.
Several recombinant proteins corresponding to the HEV capsid
protein have been shown to induce speciﬁc antibodies in animals
and to protect against liver injury following subsequent challenge
with the virus.63 In addition, an HEV DNA vaccine has also been
shown to induce serum anti-HEV production in cynomolgus
macaques and to protect against re-challenge with a heterologous
HEV strain. As a potential human HEV vaccine, a 56 kDa truncated
HEV ORF2 protein has been produced from a recombinant
baculovirus that forms virus-like particles. This vaccine has
undergone safety and efﬁcacy studies in humans. In the phase I
trial, this recombinant protein was given in an alum-adjuvant
formulation and induced the production of anti-HEV among
healthy volunteers in a dose-dependent manner.63 In the subse-
quent phase II–III efﬁcacy trials, nearly 2000 volunteers from the
Nepalese Army who lacked detectable anti-HEV antibodies
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or a matched placebo. Each treatment was given as three doses (at
0, 1, and 6 months) and volunteers were followed up for more than
2 years.64 Clinically overt acute hepatitis E occurred less frequently
among vaccine recipients who completed the three-dose schedule
than among placebo recipients, with a vaccine efﬁcacy rate of 95%.
A lower efﬁcacy rate of 86% was observed after administration of
two doses of the vaccine. Further studies are needed on the safety
of this vaccine for pregnant women, children, and certain other
groups, such as persons with chronic liver disease. The study
focused on clinical disease rates and did not look at the HEV
infection rate; thus it remains unclear whether the use of the
vaccine will reduce rates of transmission of HEV in a community.
Also, it was found that, by the end of the follow-up duration, the
titers of anti-HEV had declined signiﬁcantly and that nearly 44% of
subjects had antibody titers below the level considered protective.
Thus, further studies are needed to determine the duration of
protection afforded by this vaccine. Unfortunately, this vaccine has
not yet reached the market. In disease-endemic regions where the
vaccine is likely to be most useful, high production costs are likely
to prevent its widespread adoption. Recently, a Chinese group
prepared another hepatitis E vaccine, named the HEV 239 vaccine.
It contains a truncated HEV capsid protein (corresponding to
amino acids 376–606) expressed in Escherichia coli that has been
puriﬁed and adsorbed on aluminum hydroxide suspended in
buffered saline.65 In a human study, all the volunteers who lacked
anti-HEV seroconverted in 1 month after receiving three doses
(20 mg each at 0, 1, and 6 months, respectively).66 After the second
dose, new HEV infections were less frequent in the vaccine
recipients than in the control subjects, indicating that the vaccine
had a protective effect. A phase III trial is currently in progress.
The exact role of the HEV vaccines remains unclear. In non-
endemic regions, a vaccine would be useful for residents who are
planning travel to an HEV endemic area, while in endemic areas a
vaccine would be useful for pregnant women and persons with
pre-existing chronic liver disease where there is a likelihood of
severe disease following HEV infection. Many factors, such as cost
considerations, the duration of protection afforded by the vaccines,
and their ability to interrupt the transmission of infection, will
decide whether HEV vaccines should be used for the general
population in endemic regions.
8. Future perspectives
The last few decades have seen major advancements in the
development of control strategies for HEV. Further efforts are
needed to develop newer and more effective antiviral agents using
advanced techniques like phage display or small interfering RNA
(siRNA) -based interference systems; this should be possible in the
near future. With the use of the phage display technique, novel
proteins or peptides speciﬁc for HEV can be detected and
characterized. These could then be used either as a therapeutic
vaccine or to develop a diagnostic test. With current advancements
in the ﬁeld of reverse genetic systems, we are now able to generate
infectious clones for many RNA viruses—this also seems possible
for HEV. The development of infectious clones would provide us
with working constructs, which would be very useful in obtaining
valuable information about the pathogenesis of HEV.
The central epidemiological question in hepatitis E research is
its unexplained high severity in pregnancy, for which there are still
no concrete answers. Pregnant monkeys experimentally infected
with HEV do not show this effect, and studies in human patients
have not adequately addressed this issue. Recent reports have
increased our understanding of the role of ORF3 in HEV
pathogenesis. The importance of this protein in HEV pathogenesis
is further reinforced by the lack of experimental infection inmonkeys by an ORF3-null virus. The role of this protein in HEV
pathogenesis needs to be investigated.
9. Conclusions
HEV is the leading cause of non-A, non-B enterically-
transmitted acute viral hepatitis in India. As the risk factors
associated with the transmission of sporadic hepatitis E are
currently unknown, we cannot recommend prevention strate-
gies at this time. Speciﬁc attention should be given to persons at
higher risk of severe illness by giving priority to the prevention
of infection in this vulnerable group during HEV outbreaks. With
the current global burden of epidemic and sporadic hepatitis E,
the high mortality among pregnant women, the severity of
autochthonous hepatitis E, and the threat caused by the
widespread prevalence of HEV infection in different populations,
expansion of epidemiological studies, especially clinical trials of
promising hepatitis E vaccine candidates, should be pursued in
endemic areas.
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